13258-85-0
Chemical Structure
Org OD 02-0
Synonym(s): 10-Ethenyl-19-norprogesterone
- CAS No.: 13258-85-0
- Formula:C22H30O2
- Molecular Weight:326.47
IUPAC Name: (8S,9S,10S,13S,14S,17S)-17-acetyl-13-methyl-10-vinyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one
InChIKey: VFNRBPBEOXXVPX-GCOBIYGJSA-N
SMILES: CC([C@H]1CC[C@@]2([H])[C@]3([H])CCC4=CC(CC[C@]4(C=C)[C@@]3([H])CC[C@]12C)=O)=O
Biological Activity: Org OD 02-0 (10-Ethenyl-19-norprogesterone) is a selective mPRα/PAQR7 agonist that can cross the blood-brain barrier. Org OD 02-0 targets mPRα with an IC50 of 33.9 nM and activates the PI3K-AKT, MAPK/ERK, and Src signaling pathways. Org OD 02-0 upregulates SERCA2, phosphorylates phospholamban, increases sarcoplasmic reticulum calcium uptake, decreases RhoA/ROCK activity, and induces vascular smooth muscle relaxation and nitric oxide production. Org OD 02-0 can be used for research on Parkinson's disease, glioblastoma, apnea, and hypertension[1][2][3][4][5][6][7][8][9][10].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Org OD 02-0 | 99.7% | Org OD 02-0 (10-Ethenyl-19-norprogesterone) is a selective mPRα/PAQR7 agonist that can cross the blood-brain barrier. Org OD 02-0 targets mPRα with an IC50 of 33.9 nM and activates the PI3K-AKT, MAPK/ERK, and Src signaling pathways. Org OD 02-0 upregulates SERCA2, phosphorylates phospholamban, increases sarcoplasmic reticulum calcium uptake, decreases RhoA/ROCK activity, and induces vascular smooth muscle relaxation and nitric oxide production. Org OD 02-0 can be used for research on Parkinson's disease, glioblastoma, apnea, and hypertension. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kovács LÁ, et al. Blood-brain barrier penetration and tissue distribution of the selective membrane progesterone receptor α (mPRα/PAQR7) agonist Org OD 02-0. Frontiers in endocrinology. 2026;17:1870020.
- [2]. Kelder J, et al. Comparison between steroid binding to membrane progesterone receptor alpha (mPRalpha) and to nuclear progesterone receptor: correlation with physicochemical properties assessed by comparative molecular field analysis and identification of mPRalpha-specific agonists. Steroids. 2010 Apr;75(4-5):314-22. [Content Brief]
- [3]. González-Orozco JC, et al. Activation of membrane progesterone receptor-alpha increases proliferation, migration, and invasion of human glioblastoma cells. Molecular and cellular endocrinology. 2018 Dec 05;477:81-89.
- [4]. Pang Y, et al. Involvement of sarco/endoplasmic reticulum Ca-ATPase (SERCA) in mPRα (PAQR7)-mediated progesterone induction of vascular smooth muscle relaxation. American journal of physiology. Endocrinology and metabolism. 2021 Mar 01;320(3):E453-E466. [Content Brief]
- [5]. Castelnovo LF, et al. Progesterone exerts a neuroprotective action in a Parkinson's disease human cell model through membrane progesterone receptor α (mPRα/PAQR7). Frontiers in endocrinology. 2023;14:1125962. [Content Brief]
- [6]. Yoshida A, et al. Changes in the conflicting nongenomic effects of progesterone in rat myometrium during pregnancy. Life sciences. 2024 Mar 01;340:122454.
- [7]. Camilletti MA, et al. Participation of membrane progesterone receptor α in the inhibitory effect of progesterone on prolactin secretion. Journal of Neuroendocrinology. 2018 Sep;30(9):e12614. [Content Brief]
- [8]. Camilletti MA, et al. mPRs represent a novel target for PRL inhibition in experimental prolactinomas. Endocrine-related cancer. 2019 May;26(5):497-510.
- [9]. Joseph V, et al. Respiratory regulation by steroids in newborn rats: a sex‐specific balance between allopregnanolone and progesterone receptors. Experimental Physiology. 2018 Feb 1;103(2):276-90.
- [10]. Pang Y, et al. Role of mPRα (PAQR7) in progesterone-induced Ca2+ decrease in human vascular smooth muscle cells. Journal of molecular endocrinology. 2019 Oct;63(3):199-213.
